GlassScriptPhysician profile
C Thomas Bevill
NPI 1619993102
$11,305.65
in general payments reported to CMS, 2019-2025
58 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $1,557 · 2021: $1,603 · 2022: $1,822 · 2023: $1,514 · 2024: $1,716 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,858.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,329.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,073.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $974.96 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $858.02 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $798.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $790.49 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $364.29 | 2019-2023 | |
| Astellas Pharma US INC | $293.40 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $278.84 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.76 | 2019-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $224.93 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.52 | 2021-2023 | |
| Abbott Laboratories | $203.07 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $199.03 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $173.65 | 2019-2023 | Xarelto |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Bevill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.